All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
CD3/CD7-IT receives Fast Track designation from the FDA for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD)
Bookmark this article
On the 14th of October 2019, the U.S. Food & Drug Administration (FDA) granted Fast Track designation to CD3/CD7-IT, for the treatment of SR-aGvHD in patients following allogeneic stem cell transplantation (allo-SCT).1 CD3/CD7-IT received Orphan Drug Designation in the US for the treatment of graft-vs-host disease (GvHD) in 2013.2
CD3/CD7-IT is designed to reset the body's immune system in life-threatening T cell‒mediated conditions and consists of combination of two antibodies (directed against T-cell antigens CD3 and CD7) both conjugated to an immunotoxin. CD3/CD7-IT has demonstrated in vivo depletion of mature T cells and NK cells with minimal treatment-related side effects, in preclinical and early phase studies.1
The FDA approval is based on a phase I/II study that showed that one week of CD3/CD7-IT treatment triggered a strong clinical response and doubled the six-month overall survival rate in SR-aGVHD patients.3
A US Phase III trial involving patients with SR-aGVHD following allo-SCT will soon begin.
- Yahoo. Xenikos receives FDA Fast Track designation for T-Guard(R) for treating steroid-refractory acute graft-versus-host disease. Weblink [Accessed 22 Oct 2019]
- Xenikos. T-Guard® Receives Orphan Drug Designation for Treatment of Graft versus Host Disease (GVHD) in the US https://www.xenikos.com/t-guard-receives-orphan-drug-designation-for-treatment-of-graft-versus-host-disease-gvhd-in-the-us/ [Accessed 22 Oct 2019]
- Groth C. et al., Phase I/II Trial of a Combination of Anti-CD3/CD7 Immunotoxins for Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2019 Apr;25(4):712-719. DOI: 10.1016/j.bbmt.2018.10.020
More about...
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox